BioLife Solutions

The antitrust waiting period under the Hart‑Scott‑Rodino Act for Repligen’s planned acquisition of BioLife Solutions expired on September 3, 2026, satisfying a key closing condition. Repligen intends to acquire all outstanding BioLife shares for $11.25 in cash plus 0.1442 Repligen common shares per BioLife share; the transaction will be executed through a two-step merger process and would make BioLife a wholly owned subsidiary of Repligen. Closing remains subject to other customary conditions, including approval by BioLife shareholders; a virtual special meeting is scheduled for October 5, 2026. Analyst reaction: TD Cowen cut its rating from Buy to Hold and lowered its price target from $33 to $31; BioLife stock is currently trading at $34.93. » More on de.investing.com

BioLife Solutions' stock rose to a new 52-week high of $35.36, nearly 98% above its yearly low; it gained 44% over the past year and 57% in the last six months. Data from InvestingPro point to an overbought RSI and currently rate the stock as overvalued. TD Cowen downgraded the stock from "Buy" to "Hold" after the announcement of an acquisition by Repligen, cutting the price target to $31; the transaction is expected to be paid about two-thirds in stock and one-third in cash. » More on de.investing.com

BioLife Solutions shares rose to a 52-week high of $33.18 and are currently trading near that level; market capitalization is about $1.61 billion. The company reported Q1 2026 revenue of $27.5 million, beating analysts' estimates, while EPS remained flat at $0.02. Repligen announced a planned takeover of BioLife Solutions at $31 per share (two-thirds stock, one-third cash), prompting TD Cowen to cut its rating to "Hold" and lower its price target. Analysts see strong growth and a return to profitability but warn of possible overvaluation. » More on de.investing.com